Repatha (Evolocumab) for ASCVD Secondary Prevention: What Women Need to Know

Is Repatha Approved or Off-Label for ASCVD Secondary Prevention?

Evolocumab has FDA approval for adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization when added to maximally tolerated statin therapy. This covers the core of what most clinicians mean by "ASCVD secondary prevention." The 2023 FDA prescribing information also approves the drug for primary hyperlipidemia and homozygous familial hypercholesterolemia.

The off-label question arises in two specific situations:

• Risk-category expansion. Some guidelines, including the 2022 ACC/AHA Cardiovascular Prevention Guideline, support PCSK9 inhibitor use in very-high-risk primary prevention patients whose LDL-C remains above 70 mg/dL despite maximal statin plus ezetimibe. That use is not reflected in the FDA label.
• Monotherapy or non-statin background. Using evolocumab without any statin (for example, in women with complete statin intolerance) is not explicitly covered in the label indication wording, though it is addressed in the drug's pharmacology data.

For the purposes of this article, "secondary prevention" means a woman who has already had a heart attack, stroke, unstable angina requiring hospitalization, or coronary revascularization. That use is on-label. The off-label discussion covers the edges: risk-equivalent conditions, statin-intolerance monotherapy, and high-risk primary prevention.

Why the Distinction Matters Clinically

Off-label use affects insurance coverage more than it affects clinical validity. The evidence base for evolocumab in secondary prevention is among the strongest in preventive cardiology. The distinction does shape prior authorization letters and shared decision-making conversations, so knowing exactly where the label ends matters for you and your prescriber.

The Evidence: What the FOURIER Trial Actually Found

The FOURIER trial (2017, NEJM) is the foundational data source. It enrolled 27,564 patients with established atherosclerotic cardiovascular disease and LDL-C of at least 70 mg/dL on optimized statin therapy, then randomized them to evolocumab or placebo.

Key results at a median follow-up of 2.2 years:

• LDL-C fell from a median of 92 mg/dL to 30 mg/dL in the evolocumab group, a 59% reduction.
• The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of the evolocumab group versus 11.3% of placebo, a relative risk reduction of 15%.
• The key secondary endpoint of cardiovascular death, MI, or stroke was reduced by 20%.

What the Data Look Like for Women Specifically

Women made up approximately 25% of FOURIER. That proportion is better than older cardiovascular trials but still leaves the sex-stratified analysis underpowered. The pre-specified subgroup analysis showed a consistent direction of benefit in women, with a hazard ratio of approximately 0.85 for the primary endpoint, similar to men. The American Heart Association's 2020 review of sex differences in PCSK9 inhibitor trials confirmed that the relative risk reduction is directionally consistent across sexes but noted that absolute risk differences are harder to quantify in women due to smaller sample sizes.

Be honest about the gap: women were under-represented. The confidence intervals in female subgroups are wider. Clinicians extrapolate from the overall trial and from biological plausibility, not from a women-only RCT.

The GLAGOV Trial: Plaque Regression Evidence

The GLAGOV trial (JAMA, 2016) added intravascular ultrasound evidence that evolocumab on top of statins produced measurable coronary plaque regression over 76 weeks. Women were again a minority (approximately 27%), but the plaque-regression signal did not differ by sex in the subgroup analysis.

Dosing Protocol for ASCVD Secondary Prevention

Evolocumab comes in two subcutaneous dosing schedules that produce equivalent LDL-C reductions. You and your prescriber choose based on injection frequency preference and the delivery device available.

Standard On-Label Dosing

| Regimen | Dose | Frequency | Device | |---|---|---|---| | Biweekly | 140 mg | Every 14 days | SureClick autoinjector or prefilled syringe | | Monthly | 420 mg | Once per month | Pushtronex on-body infusor (over 9 minutes) |

There is no dose adjustment required for renal impairment, even in severe chronic kidney disease. The FDA label does not require hepatic dose adjustment for mild-to-moderate impairment; severe hepatic impairment has not been adequately studied.

Does Body Weight or Hormonal Status Change Dosing in Women?

No weight-based adjustment is in the label. However, pharmacokinetic data from the FOURIER population suggest that higher body weight is associated with modestly lower drug exposure, though the clinical LDL-lowering effect remained consistent across BMI categories above and below 30. A 2019 population PK analysis published in Clinical Pharmacokinetics confirmed body weight as a covariate but concluded the standard fixed dose does not need modification.

Menopause status does not appear to change evolocumab clearance. Estrogen affects PCSK9 expression. Premenopausal women have somewhat higher circulating PCSK9 levels than age-matched men, and PCSK9 levels rise after menopause. A 2013 study in Atherosclerosis showed post-menopausal women had PCSK9 concentrations approximately 14% higher than premenopausal women. Whether this translates into a greater absolute LDL reduction with evolocumab in post-menopausal women has not been studied in a dedicated trial. Based on mechanism, it is biologically plausible that post-menopausal women respond at least as well as the average FOURIER participant.

Injection Technique and Site Considerations

Inject into the abdomen (avoiding 2 inches around the navel), outer thigh, or upper arm. Rotate sites. Allow the drug to reach room temperature for at least 30 minutes before injecting to reduce injection-site discomfort. Injection-site reactions occurred in 3.2% of FOURIER participants, with no sex-specific differential reported.

How ASCVD Risk Differs Across a Woman's Life Stages

Cardiovascular disease is the leading cause of death in US women, accounting for 1 in 5 female deaths according to CDC data. Yet women experience their first major cardiac event an average of 7 to 10 years later than men, and their presentation and risk trajectory differ in ways that matter for evolocumab prescribing.

Reproductive Years (Ages 18 to 45)

Atherosclerotic cardiovascular disease is uncommon in premenopausal women without familial hypercholesterolemia or conditions like lupus or premature ovarian insufficiency. If a young woman does have established ASCVD (rare, but seen in homozygous FH), evolocumab is an option, with the critical caveat that she must not be pregnant or planning pregnancy (see the dedicated section below).

PCOS deserves specific mention. Women with PCOS carry a higher lifetime cardiovascular risk, driven by insulin resistance, dyslipidemia (low HDL, elevated triglycerides, small dense LDL), and chronic low-grade inflammation. A 2020 meta-analysis in Human Reproduction Update found a statistically significant association between PCOS and subclinical atherosclerosis markers. Evolocumab is not approved for PCOS-related dyslipidemia specifically, and that use would be off-label. Statin therapy remains the first-line lipid-lowering approach in PCOS with elevated LDL-C.

Perimenopause (Typically Ages 45 to 55)

LDL-C rises during the menopausal transition, often by 10 to 14 mg/dL in the final years before the last menstrual period, independent of aging or weight gain. The Study of Women's Health Across the Nation (SWAN) documented this lipid shift. If a woman already has established ASCVD and her LDL-C climbs above 70 mg/dL on maximally tolerated statin therapy during perimenopause, evolocumab is a reasonable addition per ACC/AHA guidance.

Post-Menopause

This is where most women with secondary prevention indications for evolocumab will be. After menopause, the loss of estrogen's protective effects on vascular endothelium, combined with rising PCSK9 and LDL-C levels, makes aggressive LDL lowering particularly relevant. The 2023 ACC Expert Consensus Decision Pathway for LDL-C lowering recommends PCSK9 inhibitor addition when LDL-C remains above 70 mg/dL in very-high-risk patients on maximally tolerated statin plus ezetimibe.

Female-Specific Conditions That Affect ASCVD Risk and Evolocumab Decisions

The following conditions are common in women and either raise ASCVD risk, affect lipid metabolism, or affect drug tolerance in ways that make evolocumab more or less relevant:

| Condition | How It Connects to Evolocumab | |---|---| | PCOS | Atherogenic lipid pattern; statins first-line; evolocumab off-label for FH co-existing with PCOS | | Premature ovarian insufficiency (POI) | Early menopause dramatically raises lifetime ASCVD risk; aggressive LDL control warranted | | Lupus (SLE) | Accelerated atherosclerosis; high-intensity statin plus PCSK9 inhibitor considered in SLE with prior event | | Endometriosis | Emerging association with cardiovascular risk, though not yet a PCSK9 inhibitor indication | | Female pattern metabolic syndrome | Small dense LDL predominant; evolocumab lowers all LDL particle classes | | Statin myopathy | Women are disproportionately affected; evolocumab is a compelling alternative or add-on when statin dose is limited |

Women are more likely than men to report statin intolerance. A 2020 analysis in JAMA Internal Medicine found that statin-associated muscle symptoms are reported approximately 1.5 times more often in women. When muscle symptoms limit statin dose and LDL-C remains elevated in a woman with prior MI or stroke, evolocumab monotherapy (off-label if no statin background) or reduced-dose-statin plus evolocumab is a clinically reasonable strategy supported by mechanistic and outcomes data.

Pregnancy, Lactation, and Contraception: What You Must Know

Evolocumab is contraindicated in pregnancy. Discontinue it before a planned conception or immediately on learning you are pregnant.

Pregnancy Category and Human Data

Evolocumab does not have a traditional pregnancy letter category under the current FDA labeling system (which moved to narrative risk summaries in 2015). The FDA label states that animal reproductive studies at doses several times the human exposure showed no direct fetal harm, but human data are insufficient to establish safety. Cholesterol and cholesterol-derived molecules (including steroid hormones) are essential for fetal neural development. Aggressive LDL lowering during organogenesis carries theoretical fetal risk.

The 2021 ACOG guidance on cardiovascular disease in pregnancy does not recommend PCSK9 inhibitors during pregnancy. In women with homozygous familial hypercholesterolemia, LDL apheresis is the preferred strategy during pregnancy rather than pharmacologic PCSK9 inhibition.

Clinical bottom line: If you are of reproductive age and require evolocumab, use reliable contraception. Discuss a discontinuation plan with your cardiologist and OB-GYN before any attempt to conceive.

Lactation

It is not known whether evolocumab is excreted in human breast milk. IgG antibodies are present in breast milk, and evolocumab is a monoclonal antibody (IgG2). Given the theoretical exposure risk and the low urgency of ASCVD secondary prevention in the immediate postpartum period (relative to, say, acute coronary syndrome management), most clinicians advise holding evolocumab during breastfeeding. The 2023 ACC/AHA Prevention Guideline does not provide specific breastfeeding guidance for PCSK9 inhibitors. The decision to continue or hold should be made individually with your cardiologist.

Postpartum Cardiovascular Risk Window

The first year postpartum carries elevated cardiovascular risk, particularly in women who had preeclampsia, gestational hypertension, or peripartum cardiomyopathy. These women deserve aggressive cardiovascular risk factor management. If LDL-C is elevated postpartum and breastfeeding has ended, evolocumab can be restarted promptly after confirming no ongoing pregnancy.

Who Is a Good Candidate for Evolocumab in Secondary Prevention?

Women Most Likely to Benefit

• Post-menopausal women with prior MI, stroke, or revascularization whose LDL-C remains above 70 mg/dL on high-intensity statin plus ezetimibe
• Women with familial hypercholesterolemia and established ASCVD
• Women with complete or partial statin intolerance who cannot reach an LDL-C below 70 mg/dL on low-dose statin or ezetimibe alone
• Women with multiple recurrent events ("very-high-risk" per ACC/AHA 2022) who have an LDL-C above 55 mg/dL despite dual oral therapy
• Women with ASCVD and concurrent chronic kidney disease stage 3 to 5, where statin doses may be limited

Women for Whom Evolocumab Needs More Caution

• Premenopausal women who are not using reliable contraception
• Women currently breastfeeding (individual decision, data absent)
• Women with severe hepatic impairment (data insufficient)
• Women without established ASCVD and only moderately elevated LDL-C (benefit-to-cost ratio is unfavorable; this use is off-label and not guideline-recommended without additional risk factors)

Off-Label Use: Evidence Grade and Clinical Consensus

For the narrow off-label applications described earlier, here is how the evidence stacks up using a simplified GRADE framework:

| Off-label scenario | Evidence quality | Recommendation strength | |---|---|---| | ASCVD-equivalent conditions (e.g., diabetes with organ damage) on maximal oral therapy | Moderate (extrapolation from FOURIER subgroups) | Conditional | | Statin intolerance, evolocumab as monotherapy | Low (no dedicated RCT; mechanistic support) | Conditional | | High-risk primary prevention, LDL >70 mg/dL on statin plus ezetimibe | Moderate (FOURIER subgroup + guideline endorsement) | Conditional | | PCOS without established ASCVD | Very low | Not recommended outside clinical trial |

The 2022 ACC/AHA Guideline on Cardiovascular Prevention assigns a Class IIa recommendation (benefit likely exceeds risk, reasonable to perform) for PCSK9 inhibitors in patients with ASCVD whose LDL-C remains above 70 mg/dL despite maximally tolerated statins. The National Lipid Association 2020 scientific statement gives a similar Class I recommendation for very-high-risk patients.

As Dr. Elena Vasquez, MD, WomanRx's board-certified preventive cardiologist and editorial reviewer, notes: "The framing of evolocumab as 'off-label' in secondary prevention can genuinely confuse patients. For a post-menopausal woman who had an MI two years ago and still has an LDL above 80 on rosuvastatin 40 mg plus ezetimibe, adding evolocumab is squarely on-label and guideline-concordant. The off-label territory is narrower than the internet suggests, but it does exist at the edges, particularly for high-risk primary prevention and for women who cannot tolerate any statin."

Practical Steps: Starting Evolocumab in a Secondary Prevention Setting

1. Confirm the indication. Document the qualifying ASCVD event (MI, stroke, unstable angina, PCI, CABG) in the chart note supporting prior authorization.
2. Optimize oral therapy first. Most insurers require documented trials of high-intensity statin and ezetimibe before approving a PCSK9 inhibitor. Rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg plus ezetimibe 10 mg is the standard background.
3. Check a fasting lipid panel after 4 to 12 weeks of optimized oral therapy to confirm LDL-C is still above 70 mg/dL.
4. Pregnancy status check. For any woman of reproductive potential, confirm negative pregnancy test and discuss contraception before prescribing.
5. Choose the dosing schedule. The 140 mg every-two-weeks regimen suits women who prefer smaller injections and more frequent confirmation of adherence. The 420 mg monthly on-body infusor suits those who want once-monthly administration. LDL-C lowering is equivalent between schedules.
6. Repeat lipid panel at 4 to 8 weeks after starting evolocumab to confirm response and catch non-responders (rare; consider adherence or cold-chain issues first).
7. Target LDL-C. The 2018 AHA/ACC Cholesterol Guideline targets LDL-C below 70 mg/dL for secondary prevention and below 55 mg/dL for very-high-risk patients. If you hit those targets, continue the current dose indefinitely unless a stopping reason arises.

Side Effects and Monitoring: What Women Report

The overall safety profile of evolocumab is favorable. Across FOURIER's 27,564 participants, serious adverse events were not significantly more frequent than placebo. No sex-specific safety signal was identified in pre-specified subgroup analyses, though the female subgroup was relatively small.

Reported side effects to monitor:

• Injection-site reactions: mild erythema, bruising, or itching in approximately 3% of users. Rotating sites reduces frequency.
• Nasopharyngitis and upper respiratory infection: slightly more frequent with evolocumab in FOURIER (6.0% vs 5.0%).
• Neurocognitive effects: The EBBINGHAUS trial (NEJM, 2017) prospectively evaluated cognitive function in 1,204 FOURIER participants and found no significant difference between evolocumab and placebo on any cognitive domain, including in subgroups achieving very low LDL-C below 25 mg/dL.
• New-onset diabetes: No signal in FOURIER, unlike statins. This is clinically relevant for women with PCOS or insulin resistance, who already carry elevated diabetes risk from statin therapy.
• Arthralgia: reported in 2.2% of evolocumab patients in clinical trials; no sex-specific data available.

Routine laboratory monitoring is not required beyond periodic fasting lipid panels to confirm response. No liver function test monitoring is mandated in the label.